Top global private equity firms Carlyle Group and TPG Capital Management are among those in talks to buy out the stakes of three PE investors in Bharat Biotech, the Indian company that has unveiled Zika vaccine candidates, for about $200 million. Advent International and Temasek Holdings, the Singapore government’s investment company, are two other contenders for the stakes, said people familiar with the development. The two-decade-old Bharat Biotech is expected to be valued at $60 .. Read more at: http://economictimes.indiatimes.com/articleshow/50893836.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
Source: Economic TimesBharat Biotech likely to be valued at $600 million as top PE firms queue up to buy stake.
Industry: Biotechnology 2016-02-08